<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558400</url>
  </required_header>
  <id_info>
    <org_study_id>PG324-CS301</org_study_id>
    <nct_id>NCT02558400</nct_id>
  </id_info>
  <brief_title>Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerie Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerie Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to
      Netarsudil (AR-13324) Ophthalmic Solution and Latanoprost Ophthalmic Solution.

      Following completion of the Month 12 study visit procedures, subjects will be offered the
      opportunity to participate in a 2-month observational (i.e., non-interventional) trial
      extension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2015</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">May 17, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in visual acuity from baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in visual field test from baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pupil size from baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">690</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>PG324 Ophthalmic Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop daily (evening) both eyes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Netarsudil (AR-13324) Ophthalmic Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop daily (evening) both eyes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost Ophthalmic Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop daily (evening) both eyes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PG324 Ophthalmic Solution</intervention_name>
    <description>1 drop daily (evening) both eyes</description>
    <arm_group_label>PG324 Ophthalmic Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil (AR-13324) Ophthalmic Solution</intervention_name>
    <description>1 drop daily (evening) both eyes</description>
    <arm_group_label>Netarsudil (AR-13324) Ophthalmic Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost Ophthalmic Solution</intervention_name>
    <description>1 drop daily (evening) both eyes</description>
    <arm_group_label>Latanoprost Ophthalmic Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older

          2. Diagnosis of open angle glaucoma or ocular hypertension in both eyes

          3. Unmedicated intraocular pressure &gt;20mmHg and &lt;36mmHg in 1 or both eyes at
             qualification visits

          4. Corrected visual acuity equivalent to 20/200

          5. Able to give informed consent and follow study instructions

        Exclusion Criteria:

          1. Clinically significant ocular disease

          2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure
             or narrow angles

          3. Unmedicated Intraocular pressure ≥36mmHg

          4. Use of more than 2 ocular hypotensive medications within 30 days of screening

          5. Known hypersensitivity to any component of the formulation

          6. Previous glaucoma surgery or refractive surgery

          7. Ocular trauma within 6 months prior to screening

          8. Any ocular surgery or non-refractive laser treatment within 3 months prior to
             screening

          9. Recent or current ocular infection or inflammation in either eye

         10. Used ocular medication in either eye of any kind within 30 days of screening

         11. Mean central corneal thickness &gt;620µm at screening

         12. Any abnormality preventing reliable applanation tonometry of either eye

         13. Clinically significant abnormalities in lab tests at screening

         14. Clinically significant systemic disease

         15. Participation in any investigational study within 60 days prior to screening

         16. Used any systemic medication that could have a substantial effect on intraocular
             pressure within 30 days prior to screening

         17. Women who are pregnant, nursing, planning a pregnancy or not using a medically
             acceptable form of birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aerie Pharmaceuticals</name>
      <address>
        <city>Bedminster</city>
        <state>New Jersey</state>
        <zip>07921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <disposition_first_submitted>April 12, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 12, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 17, 2018</disposition_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

